BioInformant

Your Global Leader in Stem Cell Market Research

Home » cynata » Page 5

Commercial Momentum Accelerates as Cynata Enters License Option Agreement with apceth GmbH & Co. KG

By Leave a Comment

In major news released today, Cynata announced that it has entered into a License Option agreement with apceth GmbH & Co. KG.  The agreement provides apceth with an option to certain uses of Cynata’s unique Cymerus™ mesenchymal stem cell (MSC) technology, exercisable by apceth into a definitive license agreement.

The relationship combines Cynata’s Cymerus MSC technology with apceth’s technologies for genetically modifying MSCs  to open up prospective new therapeutic fields, particularly the treatment of cancer.  This substantially broadens the commercial horizons for Cymerus, as it provides both an immediate cash payment as well as the potential to provide substantial license revenue in the form of milestones and royalties on eventual product sales.  Cynata will work with apceth in the coming months to plan out the development path for the scope of the agreement and also explore other areas into which the relationship could be extended. [Read more…]

Imagine Increasing Revenue from Stem Cell Products and Decreasing Risk

By Leave a Comment

We have helped hundreds of the top companies increase revenue from stem cell products and decrease risk. The key is targeted market intelligence, because it will help you to approach institutional investors for fundraising rounds, guide internal decision-making within your company, and reduce the risk that has traditionally accompanied new product development. Simply put, it will help you make smarter decisions, faster.

Whether or not you can invest in the recently released global strategic report, “Stem Cell Research Products – Opportunities, Tools, and Technologies,” the following is an important introduction to the stem cell research products marketplace, including key trends and future projections. [Read more…]

BioInformant Releases Mesenchymal Stem Cell Industry Report with Traditional Metrics and New Social Analytics

By Leave a Comment

View on PRNewswire or read the full press release below.

PRESS RELEASE; Washington, DC; November 21, 2015 — BioInformant, the only market research firm to exclusively serve the stem cell sector, announces the release of its global strategic report, “Mesenchymal Stem Cells – Advances and Applications.” Published November 2015, it presents 250 pages of coverage for the rapidly-evolving mesenchymal stem cell (MSC) industry.

Called the “most innovative market research firm in the world,” BioInformant tracks MSC industry metrics using continuously maintained dashboards combined with systems to trigger alerts when data exhibits unexpected variation.

A unique attribute of BioInformant is that its management team comes from a BioInformatics background – the science of collecting and analyzing complex biological data. BioInformant is the only known research firm to apply these data analysis techniques to the field of market research. This is important, because 2015 saw the first “thaw and use” ink to make MSCs readily available for 3D printing (RoosterBio and CELLINK), a novel manufacturing approach to produce a nearly unlimited supply of MSCs from iPSCs derived from a single donor (Cynata Therapeutics), and the recommendation for approval of a MSC product in Japan (JR-031 developed by Mesoblast’s Japanese partner, JCR Pharmaceuticals Co. Ltd). It is clear that the scope of the MSC industry is expanding and advanced analytics are required.

The report describes the current status of MSC research, the ongoing clinical trials involving MSCs, late stage MSC clinical trials, and possible uses of MSCs in cell therapy. Because MSCs are a sub-segment of the broader cell therapy (CT) and regenerative medicine (RM) markets, it also gives an overview of the regenerative medicine industry and overall cell therapy industry.

Importantly, BioInformant is always innovating. It tracks traditional market metrics, which include trend rate data for MSC clinical trials, scientific publications, grants, patents, product launches, new market entrants, acquisitions, and industry deal-making. However, it also tracks recently discovered social analytics, which are metrics derived from social media sites, search engines, online advertising platforms, and more. It is the only known research firm to take this duel-approach to market analysis.

Founded in 2006 in Washington, DC, BioInformant is distinctively suited to tracking the MSC industry, because it has been following the industry for a decade, providing a robust database of historical data.

BioInformant research has been cited on prominent news outlets that include the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, the Center for BioNetworking, and more. BioInformant also serves notable clients across the stem cell spectrum, with Fortune 500 companies on its client list that include GE Healthcare, Pfizer, Goldman Sachs, Beckton Dickinson, and many more.

Click here to view the full Executive Summary and Table of Contents: https://bioinformant.wpengine.com/product/mesenchymal-stem-cells-advances-and-applications/.

About BioInformant

In addition to offering cutting-edge market intelligence, BioInformant operates a stem cell industry blog at www.BioInformant.com which is nearing 100K views per month and has a subscriber base of stem cell industry executives and investors approaching 10K. It is a company goal to reach 500K views by mid-2017.  BioInformant’s President/CEO, Cade Hildreth, is a media expert on stem cell industry topics, recently conducting interviews with the Wall Street Journal and Los Angeles Business Journal.

Press Contact

Cade Hildreth, President/CEO
Hildreth@BioInformant.com
703-859-7617

BioInformant's World-Class Clients